Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8366872 | 0.88 | EPHX2 (0.75) | EPHX2KMT2AMEN1FABP7FABP5 | |
| SCHEMBL5787501 | 0.87 | EPHX2 (0.51) | EPHX2KMT2AMEN1MDM2MAOA | |
| SCHEMBL17151439 | 0.87 | EPHX2 (0.74) | EPHX2KMT2AFABP7FABP5MAOA | |
| SCHEMBL30094161 | 0.87 | EPHX2 (0.74) | EPHX2KMT2AFABP7FABP5MAOA | |
| SCHEMBL9632825 | 0.86 | EPHX2 (0.64) | EPHX2KMT2AMEN1FABP7FABP5 | |
| SCHEMBL694267 | 0.86 | EPHX2 (0.64) | EPHX2KMT2AMDM2FABP7FABP5 | |
| SCHEMBL38658529 | 0.86 | EPHX2 (0.64) | EPHX2KMT2AMDM2FABP7FABP5 | |
| SCHEMBL14647849 | 0.86 | EPHX2 (0.64) | EPHX2KMT2AMEN1FABP7FABP5 | |
| SCHEMBL8366871 | 0.86 | EPHX2 (0.64) | EPHX2KMT2AMDM2CASP3NPC1 | |
| SCHEMBL8472723 | 0.86 | EPHX2 (0.64) | EPHX2KMT2AFABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566334-B1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| CN-103025164-B | The control release of medicine from solid support | 普罗林科斯有限责任公司 | 2017-03-08 | — | — | CN | disclosed |
| EP-2566335-B1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-103025165-B | From the controlled release of macromolecular conjugates | 普罗林科斯有限责任公司 | 2016-06-08 | — | — | CN | disclosed |
| US-8946405-B2 | Controlled release from solid supports | PROLYNX LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8754190-B2 | Controlled release from macromolecular conjugates | PROLYNX LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8703907-B2 | Controlled drug release from dendrimers | PROLYNX LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC | 2013-05-09 | — | — | US | disclosed |
| CN-103025164-A | Controlled drug release from solid supports | PROLYNX LLC | 2013-04-03 | — | — | CN | disclosed |
| CN-103025165-A | Controlled release from macromolecular conjugates | PROLYNX LLC | 2013-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | SLC43A1, ABCB1, NAPA | EPHX2 2949/4885KMT2A 2288/4885MEN1 1584/4885 |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | SLC43A1, SLC47A1, SLC47A2 | EPHX2 3421/4885KMT2A 3288/4885MEN1 1427/4885 |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | ABCB1, ABCB11, GUSB | EPHX2 878/4885KMT2A 3975/4885MEN1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.